Jade Biosciences Doses First Patient in Phase 1 Trial of Autoimmune Drug JADE201

Jade Biosciences Starts Human Testing for JADE201

Jade Biosciences has announced that the first participant has been dosed in its first-in-human phase 1 clinical trial for JADE201.

JADE201 is an investigational monoclonal antibody being developed for autoimmune diseases. The drug is designed to target the B cell activating factor receptor, also known as BAFF-R.

The company expects interim clinical data from the study in 2027.

This marks an important milestone for Jade Biosciences as the company continues building its autoimmune disease pipeline.

What Is JADE201?

JADE201 is a half-life extended, afucosylated monoclonal antibody designed to remove harmful B cells from the body.

The therapy works through two mechanisms:

• Enhanced antibody effector function 

• Blocking BAFF signaling pathways 

The goal is to create deeper and longer-lasting B cell depletion compared to older B cell-targeted therapies.

According to the company, JADE201 was specifically designed to improve some of the common problems seen with currently available B cell therapies, including:

• Resistance mechanisms 

• Weak depletion in tissue areas 

• Frequent dosing requirements 

The company believes the drug could potentially become a differentiated treatment option across several autoimmune diseases.

Why BAFF-R Is Important in Autoimmune Diseases

BAFF-R plays a major role in the survival and activity of B cells.

In many autoimmune diseases, abnormal B cell activity contributes to inflammation and tissue damage. Because of this, therapies targeting BAFF-R are being explored as potential treatment approaches for multiple autoimmune disorders.

Andrew King explained that JADE201 was designed to go beyond first-generation B cell therapies by combining stronger effector function with extended half-life.

According to him, this approach may help achieve deeper and more durable B cell depletion while allowing infrequent subcutaneous dosing for patients.

Details About the Phase 1 Clinical Trial

The ongoing first-in-human study is a randomized and placebo-controlled phase 1 trial.

The study is evaluating single ascending doses of JADE201 in participants with rheumatoid arthritis.

Researchers will mainly assess:

• Safety of the drug 

• Tolerability 

• Pharmacokinetics 

• Pharmacodynamics 

The study will also measure important biomarkers, including:

• BAFF-R occupancy 

• Soluble BAFF levels 

• B cell profiling 

The company plans to use data from rheumatoid arthritis patients to help prioritize future autoimmune disease indications for JADE201.

What Preclinical Studies Showed

Before entering human trials, JADE201 was evaluated in preclinical studies using non-human primates.

According to Jade Biosciences, the drug demonstrated:

• Dose-dependent BAFF-R occupancy 

• Sustained B cell depletion 

• Extended half-life 

The company says these findings support the possibility of infrequent dosing schedules in humans.

The preclinical data also showed high-affinity binding to BAFF-R, which may help improve treatment durability.

Why This Development Matters

Autoimmune diseases continue to represent a major unmet medical need worldwide.

Although several B cell-targeted therapies are already available, many patients still experience incomplete responses, relapse, or treatment burden due to regular dosing schedules.

Jade Biosciences is trying to position JADE201 as a next-generation therapy that could potentially improve long-term disease control while reducing dosing frequency.

The company also sees broader potential beyond rheumatoid arthritis because BAFF-R biology is linked to several autoimmune conditions.

About Jade Biosciences

Jade Biosciences is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases.

The company’s lead programme is JADE101, which targets the cytokine APRIL and is currently being studied for immunoglobulin A nephropathy.

Jade’s pipeline also includes:

• JADE201, an anti-BAFF-R monoclonal antibody 

• JADE301, an undisclosed antibody candidate 

The company was launched using assets licensed from Paragon Therapeutics, which was founded by Fairmount.

Conclusion

The dosing of the first patient in the JADE201 phase 1 study marks an early but important step for Jade Biosciences in the autoimmune therapy space.

With interim data expected in 2027, the study could provide early insights into the drug’s safety profile and its potential to treat rheumatoid arthritis and other autoimmune diseases.

If successful, JADE201 may offer a new option for patients needing deeper and longer-lasting B cell depletion with less frequent dosing.